other material
confidence high
sentiment positive
materiality 0.75
Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise
Royalty Pharma plc
- PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.
- Royalty Pharma's Evrysdi royalty ownership increases from 81% to 90.5% (before cap).
- Evrysdi (SMA drug) generated 2023 sales of ~CHF 1.4B ($1.6B), up 39% YoY at CER.
- Total upfront investment in Evrysdi royalties now $1.9B; effective royalty rate 7.2%-14.5%.
- PTC retains option to sell remaining 9.5% royalty for $250M less royalties received until Dec 2025.